Get the Stockscreener App
23.30
6.07%
-1.505
After Hours:
23.78
0.485
+2.08%
Maze Therapeutics Inc stock is traded at $23.30, with a volume of 1.27M.
It is down -6.07% in the last 24 hours and up +69.54% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$24.80
Open:
$24.88
24h Volume:
1.27M
Relative Volume:
4.34
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+46.69%
1M Performance:
+69.54%
6M Performance:
+106.15%
1Y Performance:
+0.00%
1-Day Range:
$22.01
$25.48
1-Week Range:
$14.75
$25.50
52-Week Range:
$6.71
$25.50
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
23.30 | 702.49M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
20,552 Shares in Maze Therapeutics, Inc. $MAZE Bought by Invesco Ltd. - MarketBeat
Can Maze Therapeutics Inc. stock continue upward trend2025 Retail Activity & Consistent Income Trade Recommendations - baoquankhu1.vn
Is it too late to sell Maze Therapeutics Inc.2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser
Maze Therapeutics stock jumps as H.C. Wainwright raises price target on dual potential - Investing.com
Maze Therapeutics price target raised to $50 from $34 at H.C. Wainwright - TipRanks
Understanding Maze Therapeutics Inc.’s price movement2025 Top Gainers & Risk Managed Trade Strategies - Newser
$150 million private placement for Maze Therapeutics - The Pharma Letter
What the charts say about Maze Therapeutics Inc. today2025 Market WrapUp & Daily Profit Maximizing Trade Tips - Newser
How to forecast Maze Therapeutics Inc. trends using time seriesPortfolio Value Report & Safe Entry Momentum Tips - Newser
Should you hold or exit Maze Therapeutics Inc. now2025 Pullback Review & Reliable Breakout Forecasts - Newser
Live market analysis of Maze Therapeutics Inc.July 2025 Patterns & Daily Technical Stock Forecast Reports - Newser
Maze Therapeutics Secures $150M in Private Placement - MSN
Statistical indicators supporting Maze Therapeutics Inc.’s strengthTrade Volume Report & Real-Time Buy Zone Alerts - Newser
Maze Therapeutics Advances Clinical Programs Amid Financial Stability - TipRanks
Is Maze Therapeutics Inc. stock reversal real or fakeJuly 2025 Breakouts & Verified Entry Point Signals - Newser
Maze Therapeutics stock price target raised to $37 at BTIG on strong data - Investing.com UK
Risk vs reward if holding onto Maze Therapeutics Inc.2025 Bull vs Bear & Daily Oversold Bounce Ideas - Newser
Sentiment analysis tools applied to Maze Therapeutics Inc.Oil Prices & Capital Efficient Trading Techniques - Newser
BTIG Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Raises Target Price to $37 - 富途牛牛
will maze therapeutics inc. stock go up soonDip Buying & High Accuracy Swing Entry Alerts - Newser
Maze Therapeutics stock price target raised to $37 at BTIG on strong data By Investing.com - Investing.com South Africa
Custom watchlist performance reports with Maze Therapeutics Inc.Insider Selling & AI Enhanced Trading Alerts - Newser
Maze Therapeutics (NASDAQ:MAZE) Trading Up 7.5%Here's What Happened - MarketBeat
Why This Biotech, Up 55%, Was Shocked By Its Own Test Results - Investor's Business Daily
Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential - Benzinga
Custom strategy builders for tracking Maze Therapeutics Inc.Dollar Strength & Risk Managed Investment Strategies - Newser
Maze Therapeutics Announces Positive First-in-Human Results - GlobeNewswire
Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday - Benzinga
Maze’s SLC6A19 inhibitor moves to Phase 2; GenFleet to go public in Hong Kong - Endpoints News
Maze Vaults on Oversubcribed Private Placement - Baystreet.ca
Why Maze Therapeutics, Up 55%, Was Shocked By Its Own Test Results - inkl
Maze Therapeutics stock climbs on trial data (MAZE:NASDAQ) - Seeking Alpha
Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened - Stocktwits
Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today – Here’s What Happened - Asianet Newsable
Maze Therapeutics rises on $150M equity offering - MSN
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) - The Manila Times
Maze Therapeutics announces oversubscribed $150.0 million private placement - MarketScreener
Maze Therapeutics announces positive first-in-human results from phase 1 trial of Mze782 - MarketScreener
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement - GlobeNewswire
$150M Oversubscribed Funding: Biotech Maze Therapeutics Attracts Major Healthcare Investors at Premium Price - Stock Titan
Will Maze Therapeutics Inc. stock go up soonStock Surge & Risk Managed Investment Strategies - Newser
Octagon Capital Advisors LP Makes New Investment in Maze Therapeutics, Inc. $MAZE - MarketBeat
Price momentum metrics for Maze Therapeutics Inc. explainedJuly 2025 Technicals & Safe Entry Trade Reports - Newser
Alyeska Investment Group L.P. Acquires New Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Multi asset correlation models including Maze Therapeutics Inc.Price Action & Free Technical Confirmation Trade Alerts - Newser
What does recent volatility data suggest for Maze Therapeutics Inc.M&A Rumor & Pattern Based Trade Signal System - Newser
Using data filters to optimize entry into Maze Therapeutics Inc.Trade Signal Summary & Real-Time Volume Triggers - Newser
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):